Have a personal or library account? Click to login
The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer Cover

The Pharmacological Profile of Cyclin-dependent Kinase (CDK) 4/6 Inhibitors: Clinical Management of Toxicity and Drug Interactions Related to CDK 4/6 Inhibitor-based Treatment in Advanced/Metastatic Breast Cancer

Forum of Clinical Oncology
Volume 10 (2019): Issue 2 (December 2019)
By: Tzelepi C. Vasiliki,  Gogadis T. Aristeidis,  Adamidis K. Christos and  Eleni T. Timotheadou  
Open Access
|Apr 2020

Authors

Tzelepi C. Vasiliki

vtzelepi@hotmail.com

424 General Military Hospital of Thessaloniki

Gogadis T. Aristeidis

424 General Military Hospital of Thessaloniki

Adamidis K. Christos

Papageorgiou General Hospital of Thessaloniki

Eleni T. Timotheadou

Papageorgiou General Hospital of Thessaloniki
DOI: https://doi.org/10.2478/fco-2019-0007 | Journal eISSN: 1792-362X | Journal ISSN: 1792-345X
Journal RSS Feed
Language: English
Page range: 2 - 14
Submitted on: May 12, 2019
|
Accepted on: Oct 7, 2019
|
Published on: Apr 5, 2020
Published by: Helenic Society of Medical Oncology
In partnership with: Paradigm Publishing Services
Publication frequency: 2 issues per year
Keywords:
Breast cancer,
CDK4/6 inhibitors,
toxicity,
drug interactions,
clinical management
Related subjects:
Medicine,
Clinical medicine,
Internal medicine,
Haematology, oncology

© 2020 Tzelepi C. Vasiliki, Gogadis T. Aristeidis, Adamidis K. Christos, Eleni T. Timotheadou, published by Helenic Society of Medical Oncology
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Previous articleVolume 10 (2019): Issue 2 (December 2019)Next article